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Human growth and development are conditioned by
insulin-like growth factors (IGFs), which have also impli-
cations in pathology. Most IGF molecules are seques-
tered by IGF-binding proteins (IGFBPs) so that exertion
of IGF activity requires disturbance of these complexes.
This is achieved by proteolysis mediated by IGFBP pro-
teases, among which the best characterised is human
PAPP-A, the first member of the pappalysin family of
metzincins. We have previously identified and studied the
only archaeal homologue found to date, Methanosarcina
acetivorans ulilysin. This is a proteolytically functional
enzyme encompassing a pappalysin catalytic domain
and a pro-domain involved in maintenance of latency of
the zymogen, proulilysin. Once activated, the protein
hydrolyses IGFBP-2 to -6 and insulin chain b in vitro. We
report here that ulilysin is also active against several oth-
er substrates, viz (azo)casein, azoalbumin, and extracel-
lular matrix components. Ulilysin has gelatinolytic but not
collagenolytic activity. Moreover, the proteolysis-resistant
skeletal proteins actin and elastin are also cleaved, as is
fibrinogen, but not plasmin and a1-antitrypsin from the
blood coagulation cascade. Ulilysin develops optimal
activity at pH 7.5 and strictly requires peptide bonds pre-
ceding an arginine residue, as determined by means of
a novel fluorescence resonance energy transfer assay,
thus pointing to biotechnological applications as an
enzyme complementary to trypsin.
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Introduction
Studies of the effect of pituitary gland activity on body
growth led to the discovery of the insulin-like growth fac-
tors (IGF)-I and -II in the late 1950s (Salmon and Daug-
haday, 1956; Daughaday, 1998). These are small peptide
hormones that are highly similar to pro-insulin and like-
wise act on glucose levels in the blood. They are present
at very high concentrations throughout the body as cir-
culating mitogens and function through interaction with
the insulin receptor and IGF-receptor (IGFR)-I, both of
which exert tyrosine-kinase activity (Yu and Rohan,
2000). A third receptor, IGFR-II, lacks kinase activity and
is thought to function as a clearance receptor for IGF-II
(LeRoith and Roberts, 2003). IGFs regulate cell process-
es such as survival and apoptosis, migration, differenti-
ation, and proliferation, as well as the cell cycle, and thus
act on somatic growth and development, which are
dependent on nutritional conditions. In addition, IGFs
intervene in energy metabolism, reproduction and lon-
gevity (Baxter, 2000; Pollak et al., 2004). As shown for
many other growth factors, IGF activity also correlates
with several diseases, including atherosclerosis, cardio-
vascular disease, diabetes and cancer (Pollak et al.,
2004; Bach et al., 2005). In addition, IGFs have a potent
mitogenic and antiapoptotic effect on various cancer cell
types. In combination with other growth factors and ster-
oids, they neutralise the effect of antiproliferative mole-
cules on cancer growth, thus contributing to metastatic
events (Bahr and Groner, 2005). Moreover, epidemiolog-
ical studies have unambiguously correlated high levels of
circulating IGF-I with prostate, breast, colorectal and lung
cancers (Holly, 2004; LeRoith and Helman, 2004; Durai
et al., 2005).
IGFs are present at ca. 100 nM in circulation, a con-
centration that is approximately 1000-fold higher than
that of insulin and of most peptide hormones (Holly,
2004). This happens because 99% of the molecules are
sequestered in binary complexes with IGF-binding pro-
teins (IGFBP-1 to -6) (Zapf et al., 1975; Baxter, 1994).
These recruiters are soluble ubiquitous 23–53-kDa fac-
tors that consist of conserved N-terminal and C-terminal
domains, the latter bearing similarity with thyroglobulin-
type I domains. IGFBPs bind IGFs (Kd ca. 0.1 nM) with a
2- to 50-fold higher affinity than their cognate receptors.
Binding is exerted through both domains, which are
linked by a non-conserved connecting mid-region or L-
domain (Hwa et al., 1999). IGFBPs modulate IGF trans-
port and IGFR binding, dramatically slowing down IGF
clearance, but also hindering their mitogenic activity
(Burger et al., 2005). Among these proteins, IGFBP-2 and
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-6 have a higher affinity for IGF-II than for IGF-I, while
IGFBP-1, -3, -4 and -5 prefer IGF-I over IGF-II (Durai et
al., 2005) and none of them binds insulin. IGFBP-3 is the
most abundant of the IGFBPs and accounts for more
than 90% of IGF binding. It is the only IGFBP that recruits
an additional element, an 80-kDa liver-derived growth-
hormone-regulated glycoprotein termed the acid-labile
subunit, as a third binding partner to produce a ternary
complex that cannot traverse the capillary. In this way,
IGFBP-3-bound IGF is kept within the vascular system
(Durai et al., 2005). In the aggregate to IGF-binding,
a number of IGF-independent functions have been
described for IGFBPs, many of which occur through
interaction with extracellular matrix (ECM) components
(Miyakoshi et al., 2001; Bach et al., 2005). Alternatively,
IGFBPs can translocate to the nucleus with the help of
importin b and act as transcriptional regulators (Mohan
and Baylink, 2002; Burger et al., 2005). Such IGF-inde-
pendent functions have implications not only in cell
growth inhibition, the promotion of apoptosis and the
modulation of cell adhesion and migration, but also in
cancer.
To perform their physiological tasks, IGFs must be lib-
erated from their IGFBP complexes and released to the
circulation. Mechanisms for this include binding of
IGFBPs to ECM components, IGFBP phosphorylation or
glycosylation, and proteolytic inactivation. Among these
options, only the last has been demonstrated to date for
all six IGFBPs, each one being the target of distinct
IGFBP proteases (IGFBPPs). Sensitivity towards proteo-
lysis of IGFBPs may depend on the presence or absence
of bound ligand (Bunn and Fowlkes, 2003) and cleavage
can be non-specific or following limited proteo-
lysis, mostly in the IGFBP mid-regions. IGFBPPs are
present both in circulation and in interstitial fluids, and
their activity is kept in check by endogenous protease
activators and inhibitors (Conover et al., 2001; Bunn and
Fowlkes, 2003; Holly, 2004). Among the IGFBPPs report-
ed are serine proteinases (complement protein 1s; kallik-
reins such as prostate-specific antigen, human kallikrein
2 and 7S nerve growth factor; plasmin; a HtrA-related
protease; seminal plasma trypsin; cathepsin G and neu-
trophil elastase; and thrombin), cysteine proteinases
(cathepsins and calpain), and metalloproteases (MPs)
from the adamalysin/ADAM (ADAM-9, -12 and -28) and
matrix metalloprotease (MMP) families (MMP-1, -2, -3,
-7, -9, -11 and -19) (Fowlkes et al., 1994; Maile and Holly,
1999; Bunn and Fowlkes, 2003; Fang et al., 2004; Burger
et al., 2005; Nakamura et al., 2005). The latter two fam-
ilies are involved in the regulation of other growth factor
families through the shedding of ectodomains of
membrane-anchored growth factors, cytokines and
receptors to increase their circulating forms (Gomis-Ru¨th
et al., 1998; Overall and Lo´pez-Otı´n, 2002; Arribas and
Merlos-Sua´rez, 2003; Blobel, 2005).
Another MP, distinct from MMPs and adamalysins/
ADAMs, specifically inactivates IGFBPs, namely human
PAPP-A, also termed pappalysin-1 or IGFBP-4 protease
(Lawrence et al., 1999; Boldt et al., 2001; Oxvig et al.,
2004). This MP was originally identified in 1972 as an
antigen present in human pregnancy plasma (Gall and
Halbert, 1972). It is ubiquitously expressed and plays
central roles in ovarian follicular development (Conover
et al., 2001), myogenesis (Kumar et al., 2005), human
embryo implantation (Giudice et al., 2002) and wound
healing (Chen et al., 2003), as well as in atherosclerosis
(Lawrence et al., 1999; Bayes-Genis et al., 2001a,b;
Thorn and Khan, 2007), early foetal stages of Down’s
syndrome development and cancer. Mature PAPP-A is a
glycosylated multidomain protein of 1547 residues,
among them 82 cysteines wSwissProt (SP) sequence
database access code Q13219x. In pregnancy, the pro-
tein is primarily present in circulation as a 500-kDa disul-
fide-linked 2:2 complex, with two subunits of the
206-residue glycosylated proform of the eosinophil major
basic protein that acts as a covalent proteinase inhibitor.
Outside pregnancy, PAPP-A circulates as a 400-kDa
homodimer (Oxvig et al., 1993, 2004; Lawrence et al.,
1999). PAPP-A is the biochemically most thoroughly
studied specific IGFBPP and has been shown to specif-
ically hydrolyse human IGFBP-4 in an IGF-dependent
manner. In addition, PAPP-A cuts human IGFBP-5 and in
this case IGF-II has been reported to have a slightly
inhibitory function (Laursen et al., 2001). In contrast,
cleavage of IGFBP-2 is enhanced by IGF binding (Mon-
get et al., 2003; Kumar et al., 2005). PAPP-A proteolytic
activity is inhibited by basic peptides derived from hep-
arin-binding domains (Monget et al., 2003). As a com-
plement to PAPP-A’s proteolytic role, other domains were
identified by sequence similarity searches. These are a
LamG-like jellyroll-fold domain, as found in proteins of
unknown function from metazoa and bacteria; three
lin12-notch repeats (LNR-1, -2 and -3); and five ca. 65-
residue sushi domains, also known as complement con-
trol protein modules (CCP1–5), encountered in a wide
variety of complement and adhesion proteins such as P-
selectin. Accordingly, PAPP-A probably has several still
undiscovered functions, thus providing an explanation for
its participation in a number of physiological processes
and its ubiquity (Laursen et al., 2002b; Boldt et al., 2004).
PAPP-A has been designated the first member of the
pappalysin family of MPs (Boldt et al., 2001), which fur-
ther comprises the paralogue PAPP-A2, also known as
PAPP-E or pappalysin-2 (SP Q9BXP8). For this protein,
which is also found in mammals, specific IGF-independ-
ent cleavage of IGFBP-5 identical to PAPP-A and partial
activity against IGFBP-3 have been reported (Farr et al.,
2000; Bayes-Genis et al., 2001b; Overgaard et al., 2001).
These pappalysins contain the sequence motif His-Glu-
Xxx-Xxx-His-Xxx-Xxx-Gly-Xxx-Xxx-His/Asp (Xxx for any
residue), a zinc-binding consensus sequence (ZBCS) that
is the hallmark of the metzincin clan of MPs. In these
metalloproteins, the three histidine/aspartate residues are
engaged in coordination of the catalytic zinc ion and the
glutamate is the general base/acid required for enzyme
activity. Sequence analysis of PAPP-A and PAPP-A2 fur-
ther revealed the presence of a conserved methionine
residue, as found in what is known as the Met-turn in
metzincins. These findings led pappalysins to be
assigned to the latter clan (Bode et al., 1993; Sto¨cker et
al., 1995; Gomis-Ru¨th et al., 1998; Boldt et al., 2001;
Gomis-Ru¨th, 2003; Oxvig et al., 2004).
Probably the most interesting function of pappalysins
is their proteolytic action on IGFBPs because of the
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implications for mechanistic studies and drug design. An
attempt to delimit the protease domain of PAPP-A within
the 170-kDa protein was made on the basis of the three-
dimensional (3D) structure of the catalytic domains of
other metzincins and secondary structure predictions.
These studies suggested an approximately 300-residue
protease domain from approximately Lys352 to Tyr664
(in all cases, residue numbering is according to the
respective SP entry), but no experimental evidence is
available to date, as this segment could not be produced
independently in a functional state. To overcome these
difficulties, we used bioinformatic searches in a novel
approach to identify a whole series of novel putative
homologues of PAPP-A including at least the catalytic
domain (Tallant et al., 2006; Garcı´a-Castellanos et al.,
2007). These can be classified into two major groups:
one features bacterial, archaeal and fungal sequences
that potentially comprise only a catalytic domain and a
pro-domain (short pappalysins), while the other includes
PAPP-A and PAPP-A2 and consists of potential multi-
domain proteins from mammals, fish, birds, amphibians
and a collagenase precursor from Cytophaga sp. (large
pappalysins). This is reminiscent of other metzincin fam-
ilies such as astacins, MMPs and adamalysins/ADAMs,
for which single- and multi-domain sequences have been
reported (Bode et al., 1993; Sto¨cker et al., 1995; Gomis-
Ru¨th, 2003).
We have produced and studied a short family member,
Methanosarcina acetivorans ulilysin, the only archaeal
pappalysin found. As previously reported, its 3D crystal
structure uncovered a novel fold under maintenance of
certain structural elements found in other metzincin
prototypes such as MMPs and adamalysins/ADAMs (Tal-
lant et al., 2006). We report here the full cloning, overex-
pression and purification procedures for two mutagenic
variants of the ulilysin precursor, proulilysin, as well as
additional comprehensive functional studies in vitro of
the mature form, to contribute to the characterisation of
this paradigm of the protease domain of pappalysins.
These findings reveal unexpected features that may be
relevant to biotechnology and have consequences for
other short and large pappalysins, and pave the way for
new strategies for the study of the catalytic domain of
PAPP-A.
Results and discussion
Heterologous recombinant protein overexpression
and purification
As pointed out previously (Tallant et al., 2006) and dis-
cussed hereafter in more detail, several constructs and
plasmids were assayed to produce the native full-length
38-kDa protein. These produced either no expression,
protein aggregation or protein that would not crystallise
reproducibly. We suspected that some of the five cys-
teine residues present in ulilysin could be responsible for
these problems. Therefore, a systematic cysteine-to-ala-
nine scan was attempted. Eventually, a clone with a
mutation at position 269 (C269A) was identified that
overcame these obstacles. In addition, a potential active-
site mutant was generated, in which the putative general
base/acid residue Glu229 imbedded in the ZBCS was
replaced by alanine (E229A). The alanine mutation of the
equivalent glutamate residue in human PAPP-A (Glu483)
had been reported to completely abolish activity and
similar findings for other metzincins have been published
(Boldt et al., 2001; Gomis-Ru¨th, 2003). The E229 variant
did not lead to the above-mentioned biophysical incon-
veniences of the wild-type construct. For both mutant
clones, Escherichia coli-based expression systems were
developed that yielded soluble and non-aggregating N-
terminally hexahistidine-tagged protein, which was puri-
fied by affinity chromatography. The tags were efficiently
removed with thrombin and the proteins obtained were
subjected to an anionic exchange chromatography step
to remove thrombin and other impurities from the non-
tagged proulilysin. Fractions containing the protein were
pooled and subjected to a final gel filtration chromato-
graphy step for polishing. Typical protein production ren-
dered yields of ca. 0.6 mg of pure protein starting from
500 ml of cell culture.
Calcium-mediated autolytic activation and pH
optimum for activity
As reported earlier, the 38-kDa form encompassing the
full-length protein sequence is actually the pro-enzyme,
which is stable but undergoes autolytic activation at two
specific sites to produce a fragment of 29 kDa, mature
ulilysin (Figure 1A, lanes 2–4; see also Tallant et al.,
2006), in the presence of calcium. In contrast, the 38-
kDa E229A mutant was inactive and non-activatable by
calcium and did not render a short form (Figure 1A, lanes
5–7), providing additional proof that the proteolytic event
is autolytic.
To further study the activation and activity on a quan-
titative basis, a fluorescence resonance energy transfer
(FRET) reaction experiment was carried out using a fluo-
rigenic custom-synthesised peptide, DABCYL-Leu-Ala-
Arg-Val-Glu-EDANS, that mimics the C-terminal cleavage
sequence within proulilysin (Tallant et al., 2006). Mass
spectrometry analysis of the untreated peptide revealed
the presence of a peak corresponding to the expected
MqH value (1086.57 Da), as well as some minor lower-
molecular-weight impurities (Figure 2A). The sequence of
the peptide was confirmed by MALDI-TOF/TOF fragmen-
tation analysis (Figure 2B,C). The sample treated with uli-
lysin C269A in the presence of calcium exhibited a peak
of mass 454.20 Da corresponding to the fragment DAB-
CYL-Leu-Ala (Figure 2D). Fragmentation of the latter ion
produced a further peak of mass 252 Da, attributable to
the DABCYL moiety. These results confirm that the fluo-
rigenic peptide had been cleaved before the arginine
residue. Active 29-kDa ulilysin C269A showed straight-
forward activity on this peptide from the beginning of the
reaction, as visualised by a hyperbolic fluorescence
curve (Tallant et al., 2006). This proved that this penta-
peptide sequence was a good substrate for the active
enzyme. Determination of the kinetic parameters govern-
ing cleavage of this substrate by mature ulilysin C269A
revealed an apparent second-order rate constant kcat/Km
of 2.867=106 s-1 M-1 (Table 1), indicative of good affinity
for and rapid turnover of this fluorigenic peptide contain-
ing an endogenous sequence.
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Figure 1 Proteolytic activity of ulilysin.
(A) Stability of purified proulilysin (0.9 mg/ml) mutant C269A (lanes 2–4) and mutant E229A (lanes 5–7) in 20 mM Tris-HCl, pH 7.5,
0.2 M NaCl, 5 mM CaCl2 over time. (B) Limited proteolysis by ulilysin C269A of human platelet fibrinogen over time. The band marked
with an asterisk was subjected to N-terminal Edman degradation (see Figure 4). (C) Proteolytic activity of ulilysin C269A on bovine
muscle actin. (D) Proteolytic activity of ulilysin C269A on bovine plasma fibronectin. (E) Casein (left) and gelatin (right) zymograms in
the presence of 5 mM CaCl2 with the amount of ulilysin C269A indicated on top.
The optimal pH for catalysis was determined by a gela-
tinase assay kit that contains DQ gelatin as a fluores-
cein conjugate. This assay is based on the fact that
gelatin is so heavily labelled with fluorescein that the fluo-
rescence is quenched. In the presence of a gelatinolytic
active moiety, highly fluorescent peptides are generated
in proportion to the proteolytic activity. These studies
revealed that ulilysin is most active at pH 7.5 under the
assay conditions used (Figure 3). This is consistent with
human PAPP-A, for which optimal cleavage of IGFBP-4
and -5 was reported at pH 8.0 (Laursen et al., 2002a)
and for which cleavage experiments in vitro are routinely
carried out at pH 7.5 (Overgaard et al., 2000; Gyrup and
Oxvig, 2007). These values, in turn, corroborate the
observation that zinc, when bound by three histidine
imidazole groups at the active site of an enzyme, is acti-
vated to provide the Zn2q-OHy species required for
nucleophilic attack of a scissile peptide bond at a pH
near 7 (Frau´sto da Silva and Williams, 2001).
Proteolytic assays of protein substrates and
fluorigenic peptide substrates
Mature ulilysin mainly cleaved IGFBP-2 to -6 in a specific
manner, but not IGFBP-1 and IGF-II. These studies sug-
gested lower efficiency in vitro of PAPP-A and PAPP-A2
against IGFBP-4 and -5 than ulilysin when using similar
detection techniques (Tallant et al., 2006). For the human
enzymes, standard assay conditions entailed a protease/
substrate ratio of approximately 1:10 or 1:20 and incu-
bation times of up to 20 h (Boldt et al., 2001; Overgaard
et al., 2001). In contrast, ulilysin produced comparable
cleavage levels (as inferred from SDS-PAGE) in our hands
at a weight ratio of 1:300 and reaction times of 2–4 h.
However, more recent detailed kinetic studies following
a different analytical approach revealed that PAPP-A
cleaved IGFBP-4 and -5 in a much more efficient manner
than ulilysin and that the hydrolysis of IGFBP-4 was
dependent on IGF binding for both proteases (Gyrup and
Oxvig, 2007). In addition to IGFBPs, ulilysin could cut
insulin chain b, but not chain a (Tallant et al., 2006).
Besides IGF-axis proteins, ulilysin was shown to pro-
cess a whole series of substrates, mainly in a selective
manner, including the general substrates (azo)casein (as
mentioned above) and azoalbumin, as well as ECM
(derived) components such as azocollagen, gelatine
(including DQ gelatin; see above) and fibronectin (Fig-
ure 1). In this context, it should be noted that ECM com-
ponents have been shown to interact with the ulilysin
substrate IGFBP-5 and to modulate its activity in vivo
(Bach et al., 2005). Activity on casein and gelatin was
further corroborated by zymography studies, which
revealed that gelatin was a better substrate than casein
(Figure 1E). Natural type-I collagens from human placen-
ta and type-IV collagen from calf skin were also assayed,
but no cleavage was detected (Tallant et al., 2006). Type-I
collagen from kangaroo tail was cleaved at 378C, but not
at room temperature. However, this substrate was also
cleaved by trypsin under the assay conditions at 378C,
although not at room temperature, as was azocollagen.
This pointed to a certain content of gelatinous material
in the purchased samples. Accordingly, we suggest that
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Figure 2 Mass spectrometry analyses of cleaved fluorigenic peptides.
(A) Spectrum of the intact DABCYL-Leu-Ala-Arg-Val-Glu-EDANS peptide and (B) after MALDI-TOF/TOF fragmentation. (C) Fragmen-
tation allows the chemical sequence of the peptide to be assessed. (D) Spectrum of the cleaved peptide, with the 454-Da peak
attributable to the DABCYL-Leu-Ala moiety. (E) Spectrum of the intact ANG-Lys-Asp-Glu-Ser-Tyr-Arg-DNK-NH2 peptide and (F) after
MALDI-TOF/TOF fragmentation. (G) Fragmentation confirms the chemical sequence of the peptide. (H) Spectrum of the cleaved
peptide, with the 468-Da peak assignable to the Arg-DNK-NH2 cleavage product.
Table 1 Ulilysin activity on fluorigenic peptides.
Substrate Cleavage Specific cleavage Km (mM) kcat (s-1) kcat/Km (M-1 s-1)
Synthetic fluorigenic peptides
FALGPA –
DABCYL-Leu-Ala-Arg-Val-Glu-EDANS q q 173.7 497.9 2.867=106
ANG-Lys-Asp-Glu-Ser-Tyr-Arg-DNK-NH2 (peptide 1) q q 220.1 555.5 2.524=106
ANG-Ala-Val-Pro-Glu-Arg-DNK-NH2 (peptide 2) q q 184.2 670.7 3.642=106
ANG-Glu-Phe-Val-Gly-Ser-Asp-DNK-NH2 (peptide 3) –
ANG-Tyr-Ala-Arg-Lys-Leu-Phe-DNK-NH2 (peptide 4) q q 88.0 192.2 2.185=106
ANG-Leu-Lys-Tyr-Phe-Asp-Ile-DNK-NH2 (peptide 5) –
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Figure 3 pH optimum for activity.
pH dependence of ulilysin activity monitored via the fluorigenic
EnzCheck DQ gelatinase assay.
Figure 4 Cleavage sequences.
Sequences recognised by ulilysin C269A for cleavage as deter-
mined by N-terminal Edman-degradation or MALDI-TOF/TOF
fragmentation. The first five cleavage sites were reported pre-
viously (Tallant et al., 2006). The only position absolutely con-
served is an arginine residue at P19.
ulilysin has gelatinolytic but not collagenolytic activity.
Moreover, the rather proteolysis-resistant skeletal pro-
teins actin and elastin were also cleaved, as was fibrin-
ogen (chain a) (Figure 1), but not plasmin nor
a1-antitrypsin, from the blood-coagulation cascade
(Tallant et al., 2006).
As mentioned above, a fluorigenic peptide mimicking
the putative C-terminal autolytic cleavage site was suc-
cessfully employed to study activity. In addition, the spe-
cific Clostridium histolyticum collagenase IV fluorigenic
substrate FALGPA, which mimics the sequence of the a
chains in triple-helical collagen, was not cut (Table 1).
This correlates well with the above-mentioned results
and points to a lack of collagenolytic activity. Further to
these analyses, a FRET assay was employed to study
proteolysis (Table 1). This assay is a further development
of one already reported and consists of five fluorigenic
peptides with a variable amino-acid sequence containing
25 different types of dipeptides in a domino arrangement
(Yang and Reymond, 2005). The peptides possess a
7-glutaramidonaphthalene-1,3-disulfonate fluorophore
(ANG) that acts as a donor attached to the peptide N-
terminus and the last residue is always a dinitrophenyl
lysine with a C-terminal carboxamide (DNK-NH2), which
acts as a fluorophore quencher. Cleavage of a peptide
bond produces an increase in fluorescence as a result of
donor-acceptor separation. Three of these peptides were
cut and two were not (Table 1). MALDI-TOF mass
spectrometry analysis of the cleavage reaction of ANG
peptide 1 (Figure 2E–H) revealed that the untreated sam-
ple showed a very clear peak corresponding to MqH at
1489.64 Da (Figure 2E). In addition, some lower-molec-
ular-weight peaks corresponding to spontaneous frag-
mentation were observed. In a MALDI-TOF/TOF
spectrum, these fragments were also observed and the
sequence could be confirmed, including the correspond-
ing ANG and DNK-NH2 modifications of the first and last
amino acids (Figure 2G,H). In the treated sample, an ion
corresponding to 468.05 Da was observed, together with
a fragmentation ion of type M-16. This correlates with the
mass of fragment Arg-DNK-NH2, suggesting that cleav-
age had occurred between the amino acids tyrosine and
arginine. The 468.05-Da peptide was subjected to further
fragmentation. This reaction gave rise to peaks present
in the TOF/TOF fragmentation spectrum of the entire
peptide (Figure 2F), thus ruling out possible artefacts.
Determination of the kinetic parameters governing cleav-
age of ANG peptide 2 by ulilysin rendered an apparent
second-order rate constant kcat/Km of 3.642=106 s-1 M-1
(Table 1), indicative of very close affinity for and rapid
turnover of this substrate. Similarly, ANG peptides 1 and
4, which also contain an arginine residue, were also very
efficiently processed, with kcat/Km values of 2.524=106
and 2.185=106 s-1 M-1, respectively, while ANG peptides
3 and 5 remained unaffected.
Search for a specificity pattern for ulilysin
Initial cleavage assays with ulilysin based on the recog-
nised sequence motifs around the N- and C-terminal
autolytic activation sites, as well as using human fibrin-
ogen chain a and bovine insulin chain b as substrates,
revealed an apparent substrate preference following the
pattern Bbb-Xxx-x-Arg-Bbb-Glu/Gln (Bbb, bulky hydro-
phobic or aromatic) (Tallant et al., 2006). However, current
information based on its behaviour towards the ANG
peptides enabled us to establish that flanking sequences
distinct from those indicated were also very efficiently
cleaved, at least in peptide substrates, so that no addi-
tional positions seem to be specifically recognised
besides P19 (Figure 4). The very high specificity of ulilysin
for an arginine residue at P19 is further underlined by the
fact that ANG peptide 5 was not cleaved at all, despite
including a lysine. Accordingly, ulilysin can be envisaged
as a very efficient protease with a strict specificity for
substrates that inject an arginine residue side chain into
the specificity pocket, thus pointing to interesting bio-
technological applications of this enzyme in protein pro-
cessing as a complement to trypsin and other proteases
that cleave after a basic residue, as utilised during pro-
teomic studies.
Inferences for the pappalysin family
The results reported here for ulilysin may have conse-
quences for functional studies of other pappalysins such
as human PAPP-A. This enzyme specifically hydrolyses
human IGFBP-4 at the Met155-Lys156 bond (see SP
P22692) (Laursen et al., 2001), human IGFBP-5 (SP
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24593) at Ser163-Lys164 (Laursen et al., 2001) and
human IGFBP-2 (SP P18065) at Gln165-Met166 (Monget
et al., 2003; Kumar et al., 2005). PAPP-A also undergoes
autolytic cleavage at Phe386-Asn387, which causes a
loss of activity, and no other substrates for PAPP-A have
yet been found. These cleavage sites do not evince a
common pattern for substrate recognition. In contrast,
ulilysin is a very efficient, broad-spectrum enzyme with a
stringent preference for peptide bonds preceding an argi-
nine residue.
An accurate structure-based sequence alignment of
ulilysin with the region thought to encompass the cata-
lytic domain of PAPP-A (for data on the ulilysin structure
and a sequence alignment see Tallant et al., 2006;
Garcı´a-Castellanos et al., 2007) reveals that residues that
are key for catalysis and substrate binding and residues
required for structural stability in the archaeal enzyme are
fully conserved in the human protein. The sequence con-
servation is especially noteworthy within the C-terminal
sub-domain in charge of substrate binding and thus of
specificity modulation. Among these residues are
Asp295 (ulilysin numbering hereafter) at the bottom of the
specificity pocket; Asn288, placed at the beginning of the
Met-turn and hydrogen-bonded with Gln305, which is
required for structural integrity; Arg308, engaged in
hydrogen bonding of the Asn235 main chain; and two
residue duos required for structural integrity in ulilysin,
Thr302-Asp258 and Trp165-Asn172. Another similarity
between the two enzymes is that activity is dependent
on calcium (Boldt et al., 2004; Tallant et al., 2006).
Inspection of the residues and protein atoms participat-
ing in ulilysin in the coordination of the two structurally
indispensable calcium cations reveals that most ligands
are provided by solvent molecules or main-chain carbon-
yl oxygen atoms (see Figure 1 in Tallant et al., 2006;
Garcı´a-Castellanos et al., 2007). Only three side chains
are actively engaged in ulilysin, Asp254, Thr259 and
Glu243. The first two are conserved in PAPP-A, while the
third one could easily be replaced by a vicinal glutamate,
Glu580 (PAPP-A sequence). These common features
strongly suggest that the catalytic domain of PAPP-A is
structurally similar to ulilysin and likewise evinces an
active-site cleft with a specificity pocket prepared to
snugly accommodate arginine residues. This hypothesis
is further supported by the very recent finding that PAPP-
A cleaves a fluorigenic pentapeptide mimicking the
C-terminal autoactivation site of proulilysin, DABCYL-
Leu-Ala-Arg-Val-Glu-EDANS (Gyrup and Oxvig, personal
communication).
Accordingly, the apparent paradox of probable struc-
tural similarity of the PAPP-A catalytic domain with the
efficient and P19-specific ulilysin, on the one hand, and
PAPP-A’s lack of specificity and narrow substrate palette,
on the other, supports a hypothesis that steric regulation
might be a mechanism to limit substrate recognition in
PAPP-A and other large pappalysins, possibly mediated
by other domains preceding and/or following the cata-
lytic protease domain (Boldt et al., 2001, 2004; Laursen
et al., 2002a). In particular, the three LNR motifs are
attractive candidates for such a restricting function, as
they have been reported to be indispensable for proteo-
lytic specificity in PAPP-A (Boldt et al., 2001, 2004; Laur-
sen et al., 2002a). These repeats are modules of ca.
35–40 residues that were first described as regulating
ligand-induced proteolytic cleavage of the Notch recep-
tor (Aster et al., 1999). They are absent from short pap-
palysins such as ulilysin (Tallant et al., 2006;
Garcı´a-Castellanos et al., 2007), although two of them
can be envisaged as a ca. 66-residue insertion replacing
the superficial 10-residue LNR-like loop observed
between two b-strands in ulilysin. A sequence alignment
of pappalysins reveals that homologues from Gloeobac-
ter violaceus and Magnaporthe grisea probably lack this
LNR-like loop, so that this structural feature may be
optional for the distinct family members. It may occur
with distinct lengths, with maintenance of the overall pro-
tease structure, and may be surface-located, which posi-
tions it for carrying out its binding functions. In large
pappalysins, these LNR motifs could restrict the access
of substrates to the active site, thus limiting the substrate
palette and specificity. The presence of such additional
modules inserted in catalytic domains has been
described for MMP-2 and -9, for which three consecutive
fibronectin type-II domains were found (Morgunova et al.,
1999). These are involved in substrate binding and are
absent in the other MMP catalytic domains (Maskos and
Bode, 2003). Another example is provided by bone mor-
phogenetic protein-1, a multidomain procollagen C-pro-
teinase of the astacin family of metzincins, which also
shows a much broader substrate profile and higher effi-
ciency in cleaving a variety of ECM proteins for its iso-
lated catalytic domain than the full-length protein. This
difference was also attributed to additional C-terminal
domains present in the latter, which modulate and restrict
the substrate specificity through their potential protein-
binding or steric-hindering competence (Hartigan et al.,
2003; Garrigue-Antar et al., 2004; Hintze et al., 2006). A
similar scenario is conceivable for PAPP-A and other
large pappalysins with a multidomain structure, where
the proteolytic potential would be kept in check by addi-
tional domains via exosite binding and/or steric hin-
drance of substrate binding.
Materials and methods
Cloning and recombinant overexpression of M.
acetivorans proulilysin C269A and E229A mutants
The procedures used were already introduced briefly in a pre-
ceding publication and are presented here in full detail for better
reproducibility (Tallant et al., 2006). A DNA fragment of 1029 bp
encoding the chemical sequence of the full-length 342-aa
38 370-Da protein MA3214 (SP Q8TL28; hereafter referred to as
proulilysin) was amplified from total genomic DNA of M. aceti-
vorans strain C2A (ATCC no. 35395) using oligonucleotides 59-
AGG GAT GTA CAT ATG GCA GAA AAA TTT GAA AG-39 as the
forward primer and 59-CAC ACT CGA GTT ACC TTG GCA TAG
GCA TTT C-39 as the reverse primer (purchased from Micro-
synth; Balgach, Switzerland) and VentR DNA polymerase (New
England Biolabs, Ipswich, MA, USA). The reaction yielded a frag-
ment containing the correct coding sequence within recognition
sites for the restriction endonucleases NdeI (59) and XhoI (39).
After digestion with these enzymes (Fermentas, Vilnius, Lithu-
ania), the fragment was cloned into different expression vectors
employing T4 DNA ligase (Roche, Indianapolis, IN, USA). The
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point mutation C269A was introduced into the wild-type clone
as inserted into plasmid pET-28a (Novagen; San Diego, CA,
USA) with 59-TCA GGC AGA TCC TAA TTT TGG AGC TCC AAG
TTA TCC ACA TGT CAG C-39 as the forward primer and 59-GCT
GAC ATG TGG ATA ACT TGG AGC TCC AAA ATT AGG ATC
TGC CTG A-39 as the reverse primer using a QuickChange PCR-
based mutagenesis reaction kit and Pfu polymerase (Stratagene,
La Jolla, CA, USA). The clone was sequenced to confirm the
presence of the desired mutation and to rule out PCR artefacts.
Plasmid pET-28a provides kanamycin resistance to the host and
adds an N-terminal hexahistidine tag and a thrombin cleavage
recognition site to the protein sequence. This means that the
tripeptide Gly-Ser-His precedes the first endogenous methionine
after digestion with thrombin. The recombinant plasmid was
introduced into Escherichia coli BL21 Star cells by heat-shock
treatment for heterologous overexpression. A typical protein pro-
duction protocol stipulated growing 500-ml bacterial cultures in
Luria-Bertani medium for 22 h at 208C after induction with 0.25
mM isopropyl-b-D-thiogalactopyranoside at an optical density of
1.2. Bacterial cultures were collected and centrifuged at 3000 g
for 30 min and the pellets were stored at -208C for further pro-
cessing. Proulilysin E229A was obtained by site-directed muta-
genesis using the wild-type expression vector as a template and
59-CCA TGC AAT CGG ACA CTG GTT A-39 and 59-CCG ATT
GCA TGG GTT GCC GT-39 as mutagenic forward and reverse
primers, respectively. Protein overexpression proceeded as
described for proulilysin C269A.
Purification of proulilysin C269A and E229A
Pellets were gently resuspended in 50 ml of buffer A (10 mM
Tris-HCl, pH 8, 20 mM imidazole, 0.5 M NaCl, 10 mM b-mercapto-
ethanol), supplemented with one EDTA-free protease inhibitor
cocktail tablet (Complete; Roche, Basel, Switzerland). Cells were
disrupted using a cell disruptor (Constant Systems, Northants,
UK) and centrifuged at 35 000 g for 30 min. The supernatant
was filtered (0.22-mm pore size; Millipore, Billerica, MA, USA)
and incubated at 48C with 2 ml of Nickel-NTA resin (Qiagen,
Venlo, The Netherlands) previously equilibrated with buffer A.
After 2 h, the sample was applied to a batch purification column
(Bio-Rad, Hercules, CA, USA) and washed with 15=4 ml of buf-
fer A. Subsequently, the protein was first washed with solutions
containing 10% and 20% of buffer B (buffer A containing 400
mM imidazole) and then eluted with a 50% (proulilysin C269A)
or 25% (proulilysin E229A) solution of buffer B. The purity of the
samples was checked by 16% tricine SDS-PAGE. The purified
hexahistidine-tagged protein samples were pooled and thrombin
was added for tag removal (Amersham, Little Chalfont, UK; 1
U/mg protein). This reaction mixture was dialysed overnight at
48C against buffer C w10 mM Tris-HCl, pH 7.5, 2 mM 1,4-dithio-
D,L-threitol (DTT), 10 mM NaClx to enhance cleavage. The reac-
tion was stopped by the addition of phenylmethylsulfonyl
fluoride (Sigma, Madrid, Spain) to the protein/protease mixture,
which was then dialysed against buffer D (buffer C adjusted to
pH 6.3). Further purification was by anionic exchange chroma-
tography on a Pharmacia UPC-900 FPLC apparatus employing
a MonoQ HR 5/5 column (Amersham) equilibrated with buffer E
(20 mM Tris-HCl, pH 6.3, 2 mM DTT). Elution was via a linear
gradient within 30 column volumes from 0% to 100% buffer F
(buffer E plus 1 M NaCl). Fractions containing tag-free 38-kDa
proulilysin C269A and E229A were identified by SDS-PAGE and
pooled and subjected to a final size-exclusion chromatography
step on a Superdex 75 HR 10/30 (Amersham) column equili-
brated with buffer G (30 mM Tris-HCl, pH 7.5, 2 mM DTT, 100
mM NaCl). The central fractions of the peak were pooled and
concentrated using Centricon-30 centrifugal filter devices (Ami-
con, Billerica, MA, USA). Concentrated protein samples (5–20
mg/ml) were stored at 48C.
Activity and pH-optimum assessment in vitro
The proteolytic activity and its pH dependence were assessed
using a fluorimetric EnzCheck gelatinase assay kit containing
DQ gelatin from pig skin as a fluorescein conjugate (Invitrogen,
Carlsbad, CA, USA) at lEXs490 nm and lEMs520 nm in a micro-
plate fluorescence reader (Victor, Perkin Elmer, Waltham, MA,
USA). The reaction mixture contained 5 ml of DQ gelatin
(1 mg/ml) and 3 ml of ulilysin C269A (0.9 mg/ml) in 100 mM
NaH2PO4/100 mM Na2HPO4 buffer adjusted to pH values from 4
to 9. Each measurement was repeated three times.
Proteolytic assays on protein substrates and
peptide-derived fluorigenic substrates
Unless otherwise indicated, proteolytic assays were performed
at a C269A concentration of 0.65 mg/ml in 50 mM Tris-HCl, pH
7.5, 5 mM CaCl2 at 378C for 2–4 h and at a protease/substrate
weight ratio of 1:100 or 1:200. Proteins assayed for proteolytic
susceptibility comprised bovine plasma fibronectin and human
plasma fibrinogen, bovine muscle actin (all three assayed at a
weight ratio of 1:125 by mixing 450 ml of substrate in 50 mM
Tris-HCl, pH 8 with 6 ml of enzyme at 0.9 mg/ml in 50 mM Tris-
HCl, pH 7.5, 5 mM CaCl2). The fluorigenic peptide substrate
N-w3-(2-furyl)acryloylx-Leu-Gly-Pro-Ala (FALGPA, Sigma) was
assessed for cleavage by ulilysin C269A at a molar ratio of 1:7
in 50 mM Tris-HCl, pH 7.5, 0.4 M NaCl by monitoring the fluo-
rescence change at 324 nm at room temperature over 4 h on
an UV/Vis Ultraspec 2000 spectrophotometer. DABCYL-Leu-
Ala-Arg-Val-Glu-EDANS was assayed at a molar ratio of 1:7 in
20 mM Tris-HCl, pH 7.5. In addition, a fluorescent assay of five
peptides of sequence ANG-Lys-Asp-Glu-Ser-Tyr-Arg-DNK-NH2
(ANG peptide 1), ANG-Ala-Val-Pro-Glu-Arg-DNK-NH2 (ANG pep-
tide 2), ANG-Glu-Phe-Val-Gly-Ser-Asp-DNK-NH2 (ANG peptide
3), ANG-Tyr-Ala-Arg-Lys-Leu-Phe-DNK-NH2 (ANG peptide 4)
and ANG-Leu-Lys-Tyr-Phe-Asp-Ile-DNK-NH2 (ANG peptide 5),
where ANG is glutirylaminonaphthalene-1,3-disulfonate-fluoro-
phore and DNK-NH2 is dinitrophenyl lysine with a C-terminal
carboxamide, was further used for cleavage studies. These pep-
tides were conditioned as 1 mM stock solutions in 1:1 dime-
thylformamide/water (v/v) by dissolving 1–2 mg of solid peptide
in an appropriate volume. For the assays, the stock solutions
were diluted with 20 mM Tris-HCl, pH 8. The assay was carried
out by mixing 5 ml of ulilysin C269A solution (0.9 mg/ml) with
the respective peptide solution and monitoring the fluorescence
change (lEXs355 nm; lEMs460 nm) using a microplate fluores-
cence reader at 308C for 2 h.
Kinetic studies on synthetic substrates
Kinetic parameters governing ulilysin C269A cleavage were
determined for DABCYL-Leu-Ala-Arg-Val-Glu-EDANS and for
ANG-peptides 1, 2 and 4. In all cases, the reactions were carried
out at the pH of maximal protease activity in 20 mM Tris-HCl,
pH 7.5 at 308C in a microplate. Initial reaction velocities were
determined at two different substrate concentrations to ascer-
tain the region attributable to a single displacement reaction fol-
lowing simple Michaelis-Menten kinetics (Polga´r, 1999). The
initial rate of reaction (n), the substrate concentration (wSx), the
rate of reaction at substrate saturation (Vmax) and the total
enzyme concentration (wE0x) were assumed to be related via the
first-order rate constant kcat and the pseudo-equilibrium Michae-
lis constant Km (the substrate concentration when nsVmax/2),
according to the following equation:
nsV ØwSx/(K qwSx)sk ØwE xwSx/(K qwSx). (1)max m cat 0 m
In a first instance, the fluorescence variation at the correspond-
ing lEX and lEM values (see above) was monitored against time
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for a fixed enzyme concentration (1 mM) and different initial sub-
strate concentrations (3, 5, 10, 20, 50, 70 and 100 mM for DAB-
CYL-Leu-Ala-Arg-Val-Glu-EDANS; 7, 17, 33, 67 and 133 mM for
the ANG peptides). The slope of the linear part of each hyper-
bolic curve allowed determination of the associated value of n.
Subsequently, the values of n (ordinate axis) were plotted versus
wSx (abscissa) and a hyperbolic equation of type ysax/(bqx) was
adjusted using the program SigmaPlot. This allowed calculation
of Vmax, Km and kcat according to Eq. (1).
Zymographic analyses
Precast Tris/glycine Ready Gel systems (Bio-Rad) containing
either gelatin (10%) or casein (12%) were employed for zymo-
graphy studies. Aliquots of 10 ml of purified protease were incu-
bated with 10 ml of 2= sample buffer w0.125 M Tris-HCl, pH 6.8,
20% (v/v) glycerol, 4% (w/v) sodium dodecyl sulfate, 0.005%
bromophenol bluex at room temperature for 5 min and then load-
ed onto the gels, which were run at 125 V with 1= running buffer
w20 mM Tris-HCl, pH 8.3, 0.2 M glycine, 0.1% (w/v) sodium dode-
cyl sulfatex, then washed twice with renaturing buffer (2.5% Tri-
ton X-100) for 2 h, and finally equilibrated with developing buffer
w40 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 0.02% (w/v) Brij 35x with/
without 5 mM CaCl2 at 378C for 20 h under gentle agitation.
Mass spectrometry studies
Matrix-assisted laser desorption/ionisation time of flight (MALDI-
TOF) and MALDI-TOF/TOF analyses were performed on a Bru-
ker Ultraflex (Bremen, Germany) mass spectrometer equipped
with a pulsed nitrogen laser (337 nm). Samples were prepared
by mixing 0.5 ml of the peptide solution with 1 ml of the matrix
solution (0.3 mg/ml a-cyano-4-hydroxycinnamic acid in ethanol/
acetone, 2:1 v/v). The mixture was then spotted on an anchor-
chip target (Bruker) and allowed to evaporate to dryness at room
temperature. Spectra were acquired in positive reflectron mode
using an acceleration voltage of 25 kV. A mixture of standard
peptides of known molecular mass in the range 750–3500 Da
(Bruker) was used for external calibration of the mass spectra.
The BioTools 3.0 software (Bruker) was used for MALDI-TOF/
TOF spectra fragment analysis.
Miscellaneous
Chemical sequencing by N-terminal Edman degradation was
performed at the Proteomics Unit of the Technical and Scientific
Service of the Barcelona Science Park, Barcelona, Spain.
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